DCVax-L, Northwest Biotherapeutics

Drug: DCVax-L
Company: Northwest Biotherapeutics
Phase: Phase III
Class: Cancer vaccine
2020 sales: $2.04 billion
Net present value: $5.5 billion

DCVax-L is a cancer vaccine, which in and of itself is grounds for controversy. Some analysts don't give this one a chance because it is a cancer vaccine based on dendritic cell technology--a field that has seen weak responses in a slate of studies. And others hate it because the company has taken the, um, unconventional approach of regularly touting individual patients' positive responses as evidence of broad efficacy. It's fine to use anecdotes to illustrate a broadly positive efficacy profile--provided you have the data in hand to back it up. Northwest Bio ($NWBO) has also trumpeted a decision in Germany to make it available to brain cancer patients. Despite the controversy, EvaluatePharma sees this one as a potential standout, a new entry that is likely to get plenty of careful attention.

For more:
Northwest Bio begins German vax trial as glioblastoma market poised to double
ASCO preview: What's the outlook for cancer vaccines?
Northwest Bio, NewLink proceed with cancer vax trials to mixed reviews

DCVax-L, Northwest Biotherapeutics
Read more on

Suggested Articles

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.

While screening Caenorhabditis elegans for genetic clues to the PI3K/Akt signaling pathway, scientists found a key protein for insulin synthesis.